Drug Trial Radar · NCT07215403
Open-Label, Multi-Stage Study to Optimize the Intraputaminal Administration of AB-1005 Using a Prescriptive Infusion Algorithm (PIA)
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Apr 30, 2028
Study completion Nov 1, 2028
Sponsor
- Lead sponsor
- AskBio IncIndustry
- Sponsor type
- Industry
- Collaborators
- Bayer
- First posted
- Oct 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 45 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to test a new way of delivering AB-1005 into the brain. The goal is to make the procedure easier and quicker to perform, while providing similar amounts of drug to the part of the brain that needs treatment. Technical (Stage 0) To test if the new delivery method (prefrontal surgical approach) can consistently deliver AB-1005 to the putamen using MRI monitoring. Technical (Stage 1) To test if the new delivery method (PIA-based infusion) can consistently deliver AB-1005 to the putamen using brain imaging by MRI. Technical (Stage 2) To confirm the new delivery method works without brain imaging by MRI, using standard operating room tools including brain imaging by CT. Safety (Stage 1 and 2) To assess the safety and tolerability of the new delivery method for AB-1005 up to 6 months after surgery
Conditions
- PARKINSON DISEASE (Disorder)
Interventions
Prescriptive Infusion AlgorithmProcedure
The study intervention is comprised of the neurosurgical procedure and the bilateral intraputaminal delivery of AB-1005.
AB-1005Drug
bilateral intraputaminal delivery of AB-1005
Primary outcomes
What the sponsor says the trial is designed to measure.
- Amount of the putamen covered by the drug at the end of infusion, assessed by MRITime frame: immediately after the intervention/procedure/surgery
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
University Hospitals Cleveland Medical Center
Cleveland, Ohio
The Ohio State University Wexner Medical Center Neurological Surgery
Columbus, Ohio
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.